English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

To the Editor—Emery et al. [1] did a valuable retrospective evaluation of 3 randomized controlled trials that addressed the clinical benefits of interleukin (IL)–2 therapy in adults with human immunodeficiency virus (HIV) infection. The analysis of the pooled data (median follow-up, 29 months) showed a nonsignificant but relevant 43% reduction in the risk of disease progression and death for subjects randomized to receive continuous infusion of IL-2, compared with those randomized to receive antiretroviral therapy alone (control group), even though 60% of the subjects in the control group received IL-2 after ∼1 year in the study. Another remarkable finding was the significantly lower plasma HIV RNA level for patients in the group receiving IL-2, relative to that for patients in the control group. A recent randomized multicenter clinical trial detected a larger decrease in the mean virus load and more likelihood of achieving a virus load of !50 copies/mL in subjects receiving IL-2, compared with subjects receiving antiretroviral therapy alone, at 1 year of follow-up [2]. Phase III trials of IL-2 therapy with antiretrovirals versus antiretroviral therapy alone are currently underway to appraise prospectively the role of IL-2 in HIV treatment. The results of these trials will be critical to defining the future use of IL-2 in this setting. Because the typical side effects of IL-2 therapy make a blinded study impossible, other aspects of the studies might affect the results. A meta-analysis [3] showed that several types of interventions (educational, behavioral, and emotional) had a weak-to-moderate effect on drug compliance and on outcomes for subjects with chronic diseases. In another study [4], patients with diabetes mellitus who believed that they had participated in the decision-making process were more likely to follow through on treatment decisions than those who did not feel that they were part of the decision-making process. An additional meta-analysis with diabetic patients found that emotional stability, internal and external motivations, perceived benefit, and supportive structure were positively associated with patient compliance [5]. Other factors that might be associated with better outcome include the amount of information and the encouragement that patients receive [6]. Subjects randomized to IL-2 therapy probably will have different experiences than subjects randomized to a control group (antiretroviral therapy alone). Those receiving IL-2 injections might make more-frequent visits to a doctor's office, as well as periodic phone calls to medical care providers, and therefore might have closer follow-up. This is reasonable to assume, …

Interleukin‐2 in Clinical Trials: Other Factors to Be Considered